search
Back to results

CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants

Primary Purpose

Diaper Rash

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CeraVe Baby Diaper Rash Cream
Desitin Maximum Strength Original Paste
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diaper Rash

Eligibility Criteria

3 Months - 18 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Healthy children (except for diaper dermatitis) between 3 and 18 months of age
  • Wearing diapers 24 hours per day
  • Clinical irritant diaper dermatitis
  • Received a Diaper Dermatitis severity score of 1.0 to 2.0 by investigator at screening visit (mild-moderate severity)
  • Parent/caregiver will not change type or brand of diaper during the study, although the diaper type will be recorded
  • No alteration of current product usage for creams, lotions, ointments, powders, soap, laundry detergents, and fabric softeners
  • A parent or guardian of minors must sign the approved Institutional Review Board consent form prior to the conduct of any study-related procedures

Exclusion Criteria:

  • Illness within past 4 days before study enrollment or any medical condition that may affect risk of study participation
  • Does not wear diapers 24 hours per day or currently being toilet trained
  • Active diagnosis or history of dermatological conditions other than diaper rash that may affect study
  • Concomitant use of medications that may affect study (e.g., antifungal, topical steroid, or topical calcineurin inhibitor)
  • Previous allergic reaction or known sensitivity to ingredients in study agents

Sites / Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago
  • Northwestern University Department of Dermatology
  • Lurie Children's Hospital Outpatient Clinic at Lincoln Park

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

CeraVe Baby Diaper Rash Cream

Desitin Maximum Strength Original Paste

Arm Description

Healthy 3-18 months old infants with mild to moderate diaper dermatitis.

Healthy 3-18 months old infants with mild to moderate diaper dermatitis.

Outcomes

Primary Outcome Measures

Change From Baseline for the Physician Assessment Diaper Dermatitis Scores to Day 14 for Each Treatment Group.
For each visit the study doctor will assess the diaper dermatitis severity with a Diaper Dermatitis Severity Score tool. In Addition, location of clinically apparent involved area will be shaded by hand onto diagram by the research personnel. Scores will be compared.

Secondary Outcome Measures

Change in Physician Assessment Diaper Dermatitis Scores to Day 7
For each visit the study doctor will assess the diaper dermatitis severity with a Diaper Dermatitis Severity Score tool. In Addition, location of clinically apparent involved area will be shaded by hand onto diagram by the research personnel. Scores will be compared.
Parents/Caregivers Daily Scores Through Duration of the Study Period
Parent/caregivers will be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a Visual Analogue Scale severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level
Assessment of Tolerability by the Infant
Parent/caregivers will be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a VAS severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level
Parent/Caregiver Rating of Satisfaction With Use of the Product
Parents/caregivers will be given a questionnaire rating the use of the study products.

Full Information

First Posted
November 20, 2014
Last Updated
February 13, 2018
Sponsor
Northwestern University
Collaborators
Bausch Health Americas, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02299206
Brief Title
CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants
Official Title
Randomized, Double-Blind, Parallel Group, Non-Inferiority Clinical Trial of CeraVe Baby Diaper Rash Cream Compared to Desitin Maximum Strength Original Paste for Management of Diaper Dermatitis in Infants
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Terminated
Why Stopped
Principal Investigator and sponsor agreed to termination.
Study Start Date
December 2014 (Actual)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
Collaborators
Bausch Health Americas, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single-center, 1:1 randomized, double-blind, parallel-group, non-inferiority controlled trial to demonstrate non-inferiority of CeraVe Baby Diaper Rash Cream compared to Desitin Maximum Strength Original Paste when administered to children with diaper dermatitis who are between 3 months to 18 months of age. Parents/caregivers of subjects in both groups will administer the product with each diaper change throughout the course of the study period. Product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period. Subjects will be assessed by the study doctor, parent/caregiver will be asked about any adverse effects. Parent/caregivers will also be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a Visual Analogue Scale severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level. Parents/caregivers will also be given a questionnaire rating the use of the study products.
Detailed Description
Visit 1 - Screening and Baseline Visit (Day 0) Subjects will be evaluated for study eligibility using inclusion and exclusion criteria. The study doctor will assess diaper dermatitis for inclusion and exclusion criteria and to verify mild to moderate severity. Once study eligibility has been confirmed, parental/guardian consent will be obtained. No washout period is necessary for this study. Location of clinically apparent involved area will be shaded by hand onto diagram by the research personnel. Study products will be dispensed to parent/caregiver, along with instructions for administration. Parent/caregivers will also be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a Visual Analogue Scale severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level. Parents/caregivers will be asked to complete the daily diary for each day of the study. Visit 2 (Day 7) Subjects will again be assessed by the study doctor. Parent/caregiver will be asked about any adverse effects in last 7 days. Visit 3 - End of study (Day 14) Subjects will again be assessed by the study doctor. Daily diaries and product will be collected at this time. Parent/caregiver will be asked about any adverse effects in last 7 days. Parents/caregivers will also be given a questionnaire rating the use of the study products.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diaper Rash

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigator
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CeraVe Baby Diaper Rash Cream
Arm Type
Experimental
Arm Description
Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
Arm Title
Desitin Maximum Strength Original Paste
Arm Type
Experimental
Arm Description
Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
Intervention Type
Drug
Intervention Name(s)
CeraVe Baby Diaper Rash Cream
Other Intervention Name(s)
CeraVe BDRC NDC Code: 0187-2221
Intervention Description
Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
Intervention Type
Drug
Intervention Name(s)
Desitin Maximum Strength Original Paste
Other Intervention Name(s)
Desitin MSOP NDC Code: 58232-0721
Intervention Description
Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
Primary Outcome Measure Information:
Title
Change From Baseline for the Physician Assessment Diaper Dermatitis Scores to Day 14 for Each Treatment Group.
Description
For each visit the study doctor will assess the diaper dermatitis severity with a Diaper Dermatitis Severity Score tool. In Addition, location of clinically apparent involved area will be shaded by hand onto diagram by the research personnel. Scores will be compared.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Change in Physician Assessment Diaper Dermatitis Scores to Day 7
Description
For each visit the study doctor will assess the diaper dermatitis severity with a Diaper Dermatitis Severity Score tool. In Addition, location of clinically apparent involved area will be shaded by hand onto diagram by the research personnel. Scores will be compared.
Time Frame
7 days
Title
Parents/Caregivers Daily Scores Through Duration of the Study Period
Description
Parent/caregivers will be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a Visual Analogue Scale severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level
Time Frame
14 days
Title
Assessment of Tolerability by the Infant
Description
Parent/caregivers will be asked to complete a daily diary that asks about changes in their baby's diaper dermatitis, a VAS severity assessment of their baby's diaper dermatitis, and observations related to product use and the baby's comfort level
Time Frame
14 days
Title
Parent/Caregiver Rating of Satisfaction With Use of the Product
Description
Parents/caregivers will be given a questionnaire rating the use of the study products.
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
18 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Healthy children (except for diaper dermatitis) between 3 and 18 months of age Wearing diapers 24 hours per day Clinical irritant diaper dermatitis Received a Diaper Dermatitis severity score of 1.0 to 2.0 by investigator at screening visit (mild-moderate severity) Parent/caregiver will not change type or brand of diaper during the study, although the diaper type will be recorded No alteration of current product usage for creams, lotions, ointments, powders, soap, laundry detergents, and fabric softeners A parent or guardian of minors must sign the approved Institutional Review Board consent form prior to the conduct of any study-related procedures Exclusion Criteria: Illness within past 4 days before study enrollment or any medical condition that may affect risk of study participation Does not wear diapers 24 hours per day or currently being toilet trained Active diagnosis or history of dermatological conditions other than diaper rash that may affect study Concomitant use of medications that may affect study (e.g., antifungal, topical steroid, or topical calcineurin inhibitor) Previous allergic reaction or known sensitivity to ingredients in study agents
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Paller, MD
Organizational Affiliation
Department of Der,matology, Feinberg School of Medicine, Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ann & Robert H Lurie Children's Hospital of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611-2991
Country
United States
Facility Name
Northwestern University Department of Dermatology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Lurie Children's Hospital Outpatient Clinic at Lincoln Park
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60614
Country
United States

12. IPD Sharing Statement

Learn more about this trial

CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants

We'll reach out to this number within 24 hrs